fbpx

News

Lundbeckfonden Ventures News

Sensile Medical wins as Innovation Leader for micropump at core of    sc2Wear Patch Pump– LEXINGTON, MA. November 23,    2015– scPharmaceuticals, Inc. today announced that its strategic partner,    Sensile Medical, was awarded the prestigious Swiss Technology Award in the category    “Innovation Leader.” The prize is the most important distinction    for innovation and technology transfer...
Paris, France - November 12, 2015 - Enterome Bioscience SA, a pioneer in the development of therapeutic solutions (drugs and diagnostics) based on the gut microbiome, announces that it has entered into a collaborative development agreement with Gustave Roussy, Europe's first comprehensive cancer centre.
Program aims to develop a new method of delivering trusted antibiotic without risk or costs associated with daily intravenous infusions.LEXINGTON, Mass., November 10, 2015 /PRNewswire/ -- scPharmaceuticals, Inc., announced today that it has commenced its pivotal trial of subcutaneous administration of the antibiotic ceftriaxone for use with the sc2Wear Patch Pump.  
Complete (100%) bioavailability after subcutaneous administration when compared with intravenous administration - Diuresis at 8 and 24 hours was equivalent to diuresis following standard intravenous administration - U.S. and EU regulatory filings anticipated in 2016 -LEXINGTON, MA. - scPharmaceuticals, Inc. today announced positive results from its pharmacokinetic and pharmacodynamics phase 3 pivotal registration trial.  The trial in...
GAITHERSBURG, Md., Oct. 22, 2015 /PRNewswire/ -- Vtesse, Inc. announced today the addition of Elizabeth Berry-Kravis, M.D., Ph.D., Professor of Pediatrics, Neurological Sciences and Biochemistry at Rush University Medical Center to its Scientific Advisory Board (SAB) and that Michael Massaro has joined the company as Vice President, Clinical Operations. Today's news comes on the heels of Vtesse's...
CERAMENTT'G Shown to Decrease Infection and Increase New Bone Growth in a Pivotal Animal Model  Lund, Sweden, (PRNEWSWIRE) October 20, 2015 - BONESUPPORTT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today announced data from the first U.S. study of CERAMENTT with Gentamicin in...
NEW YORK, Oct. 9, 2015 /PRNewswire-iReach/ -- River Vision Development Corp. (RVDC) today announced the completion of enrollment of a Phase 2 clinical study of RV001 (teprotumumab) for the treatment of Graves' Orbitopathy (GO). RV001 is a fully human IGF-1 receptor antagonist antibody with a safety database comprised of more than 700 cancer patients. The study is being conducted at 15 sites...
·         50% Less Fracture Rates with CERAMENTT with Gentamicin·         50% Less Infection Recurrence with CERAMENTT with Gentamicin·         313 Patients Total in All Groups with a Minimum of 1 Year Follow-UpLund, Sweden, (PRNEWSWIRE) October 6, 2015 - BONESUPPORTT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic...
During its first year of operations, Vtesse advances lead program into late-stage, pivotal trial and launches www.theNPCstudy.com- Goal is to establish a clear foundational data set on the safety and efficacy of VTS-270 for treatment of NPCGAITHERSBURG, Md., Sept. 28, 2015 /PRNewswire/ -- Vtesse, Inc. today announced that the first three patients have been screened for inclusion in...
1 39 40 41 42 43 65

Lundbeckfonden Ventures

News

Acacia Pharma Group PLC – Issue of Equity on Exercise of Options/Vesting of Performance Share Awards
8. May 2020
Acacia Pharma Group PLC – Issue of Equity on Exercise of Options/Vesting of Performance Share Awards
7. May 2020
Acacia Pharma Group PLC – Alessandro Della Chà appointed as Director of Acacia Pharma Group plc
9. April 2020